214-556-0555 (Direct) 888-781-5558 (Toll Free) treva@swscoli.com

Ioannis Avramis, MD

Business Addresses

Baylor Scoliosis3454Plano
4708 Alliance Blvd. Suite 810
Plano, Texas

Fort Worth
1650 West Magnolia Blvd, Suite 210
Fort Worth, Texas

McKinney
5236 W. University, Ste. 2900
Mckinney, Texas

Phone: 214-556-0555
Fax: 972-985-4797

Current Title and Affiliations

Pediatric and Adult Spine Surgeon
Physician, Southwest Scoliosis Institute

Education

August 2002 – June 2006
University of California Davis School of Medicine
Doctor of Medicine

August 1998 – March 2002
University of California Los Angeles
Bachelor’s of Science – Biology – Summa cum Laude

Post-Graduate Training

August 2011 – July 2012
University of California Davis Medical Center
Fellowship – Pediatric & Adult Spine Surgery

July 2007 – June 2011
Los Angeles County + University of Southern California
Residency – Orthopaedic Surgery

June 2006 – June 2007
Los Angeles County + University of Southern California
Internship

Licensures / Board Certifications

Texas Medical Board State License
California Medical Board State License

Society Memberships

American Academy of Orthopedic Surgeons
North American Spine Society
Eagle Scout
The National Society of Collegiate Scholars
Gold Key Honor Society
Phi Beta Kappa Member

Research

Childrens Hospital Los Angeles, Research Student 1995-2010
Summary of Research:
Pre-clinical and clinical research investigating cytotoxic chemotherapy agents alone and in combination against hematological cancers, mostly ALL Leukemia, in Phase I, IIa and IIb trials.
Investigation in pre-clinical and clinical research examining the effect of Vascular Endothelial Growth Factor (VEGF) in human refractory leukemia cells and in human brain tumor cells (glioblastoma).

UCLA, Department of Neurobiology, August 1999- June 2000
Summary of Research:
Surgical removal of hippocampus from 3-day old mice and culture for neurotransmitter identification. Patch clamping of cells to test membrane potential variations.

UCLA, Deparment of Chemistry and Biochemistry, May 2001- July 2001

Summary of Research:
Creation of bacculovirus vector containing Groucho mutants and expression in insect cells in order to characterize the binding interaction of Groucho.

USC, Department of Orthopaedic Surgery, May 2008- present
Summary of Research:
Comparison of the cross sectional area of the supraspinatus fossa on MRI and Radiographs of patients with supraspinatus impingement to a control group.
Evaluation of shoulder radiographs value in determining supraspinatus impingement and stenosis of the supraspinatus fossa.

CHLA-USC, Department of Orthopaedic Surgery, August 2008- 2011
Summary of Research:
Case series of open reduction internal fixation of sacral facet fractures in high level pediatric athletes.

UC Davis, Department of Orthopaedic Surgery, August 2011- present
Summary of Research:
Determination of factors leading to catastrophic failure of laminoplasty.

Publications

Avramis, I.A., Kwock, R., and Avramis, V. I. Taxotere and vincristine inhibit the secretion of the angiogenesis-inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res. 21:2281-2286, 2001.

Avramis, V. I., Kwock, R., Avramis, I. A., Cohen, L.J., and Inderlied, C. Synergistic Antiviral Effect of PEG-Asparaginase (ONCASPAR) With Protease Inhibitor Alone and in Combination with RT Inhibitors Against HIV-1 Infected T-cells: A Model of HIV-1-Induced T-cell Lymphoma. IN VIVO, 15:1-10, 2001.

Majlessipour F, Avramis IA, Kwock, R, Weinberg, KI, and Avramis VI. The Combination Regimen of Idarubicin and Taxotere is Effective Against Human Drug-Resistant Leukemic Cell Lines. Anticancer Res., 22(3):1361-1368, 2002.

Avramis IA, Christodoulopoulos G, Suzuki A, Laug WE, Gonzalez-Gomez I, McNamara G, Sausville EA, Avramis VI. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother. Pharmacol., Dec;50(6):479-489, 2002.

Avramis IA, Laug WE, Sausville EA, and Avramis VI. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (Adaphostin) and/or STI571 (Imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother. Pharmacol., 52(4):307-318, 2003.

Panosyan, E. H., Seibel, N. L., Gaynon, P.S., Sather, H., Avramis, I.A., Martin-Aragon, S., Franklin, J., Nachman, J., Ettinger, L., La, M., Steinherz, P., Cohen, L.J., Siegel, S.E., and Avramis, V. I. Asparaginase Antibody and Asparaginase Activity in Children with Higher Risk Acute Lymphoblastic Leukemia: Children’s Cancer Group Study CCG-1961. J Ped Hema Oncol, 26:217-226, 2004.

Grigorian R. S., Panosyan E. H., Seibel, N. L., Gaynon, P. S., Avramis, I. A., and Avramis, V. I. Changes in amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In vivo, 18:107-112, 2004.

Panosyan, E. H., Grigorian, R.S., Avramis, I.A., Seibel, N. L., Gaynon, P.S., Fingert, H., Siegel, S.E., and Avramis, V. I. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res.: 24: 1121-1126, 2004.

Ioannis A. Avramis, Eduard H. Panosyan, Fred Dorey, John S. Holcenberg, Stuart E. Siegel, and Vassilios I. Avramis. Vascular endothelial growth factor (VEGF) serum levels predict treatment outcome in pediatirc patients with standard risk acute lymphoblastic leukemia (SR ALL): a case control study (Children’s Cancer group study, CCG-1962). J Clin Cancer Research, 12(23): 6978-84, 2006.

Skaggs DL, Avramis I, Myung K, Weiss J. Sacral Facet Fractures in Elite Athletes. Spine 15;37(8):E514-517, 2012.

Absrtacts

Ioannis A. Avramis, Garyfallia Christodoulopoulos, Richard Kwock, Edward A. Sausville, and Vassilios I. Avramis. NSC 680410 AND NSC 642492: Novel Antileukemic Agents with Activity in p53-null Leukemias In Vitro. Proc. Am. Assoc. for Cancer Res., 42:189, Abstr # 1015, 2001.

Garyfallia Christodoulopoulos, Richard Kwock, Ioannis A. Avramis, Fae Majlessipour and Vassilios I. Avramis. Chemosensitivity Studies in a Human Leukemia Model Resistant to Ara-C plus Asparaginase (ASNase). Proc. Am. Assoc. for Cancer Res., 42:204, Abstr # 1095, 2001.

Avramis, I.A., Kwock, R., and Avramis, V.I. Taxotere (TXR) & Vincristine (VCR) Inhibit Secretion of Vascular Endothelial Growth Factor (VEGF) by Human Leukemia T-cell Lines. Proc. Am. Soc. Clin Oncol. (ASCO), 20:371a, Abstr. # 1481, 2001.

Christodoulopoulos, G., Avramis, I.A., Suzuki, A., Kwock, R., Laug, W.E., Sausville, E.A., and Avramis, V.I. In Vitro and In Vivo Anticancer Evaluations of Two Novel Tyrosine Kinase Inhibitors NSC 680410 and NSC 642492. Anticancer Research, 21:1580, Abstr., #109, 2001

Avramis, V.I., Panosyan, E., Avramis, I. A., Gaynon, P., Sather, H., Ettinger, L., Cohen, L., Seibel, N. Asparaginase (ASNase) Activity, Anti-ASNase Antibody (Ab), and Amino Acid Deamination in Children With Higher Risk Acute Lymphoblastic Leukemia (HR ALL) (CCG-1961). Oral presentation at the 3rd Biennial Hannover Symposium on Childhood Leukemia, Hanover, Germany, February 2002.

Avramis, I.A., Christodoulopoulos, G., Suzuki, A., Laug, W.E., Gonzalez, I., Erdreich-Epstein, A., McNamara, G., Sausville, E. A., and Avramis, V.I. In Vitro and In Vivo Evaluations of the Tyrosine Kinase Inhibitor NSC680410 Against Human Leukemia and Glioblastoma Lines. Proc. Am. Assoc. for Cancer Res., 43:336, Abstr # 1666, 2002.

Avramis, I.A., Sausville, E. A.,and Avramis V.I. Combination studies between NSC680410 and anti-leukemic cytotoxic drugs in human leukemia lines. Proc. Am. Assoc. for Cancer Res., 43:338, Abstr # 1678, 2002.

Avramis, V. I., Panosyan E., Avramis, I.A., Martin-Aragon, S., Gaynon, P., Sather, H., Ettinger, L.J., Cohen, L., and Seibel, N. Anti-asparaginase (ASNase) antibody (Ab) and ASNase activity in children with higher risk acute lymphoblastic leukemia (HR ALL) (CCG-1961). Proc. Am. Soc. Clin. Oncol., 21:399a, Abstr. # 1592, 2002.

Panosyan, E., Avramis, I.A., Seibel, N.L., Grigorian, R., Gaynon, P.S., Sather, H., Siegel, S. E., and Avramis, V.I. Glutamine (Gln) deamination by asparaginases (ASNases) in children with higher risk acute lymphoblastic leukemia (HR ALL), (CCG-1961 study). Blood, 100:759a, Abstr# 3006, 2002.

Panosyan, E., Avramis, I.A., Seibel, N.L., Grigorian, R., Gaynon, P.S., Sather, H., Siegel, S. E., and Avramis, V.I. Asparagine (Asn) deamination in children with higher risk acute lymphoblastic leukemia (HR ALL) at lower asparaginases (ASNase) activity levels (CCG-1961 study). Blood, 100:760a, Abstr# 3007, 2002.

Avramis, I.A., Panosyan, E.H., Grigoryan, R.S., Sather, H., Gaynon, P.S., Siegel, S.E., Holcenberg, J.S., Avramis, V.I. Correlation of vascular endothelial growth factor (VEGF) serum levels and outcome in SR ALL patients (pts).: A case-control study (CG-1962). Proc. Am Soc Clin Oncol. 22: p.808, Abstr. #3247, Chicago, Ill, 2003.

Panosyan, E.H., Grigoryan, R.S., Avramis, I.A., Seibel, N.L., Gaynon, P.S., Siegel, S.E., and Avramis, V.I. Deamination of glutamine (Gln) is a prerequisite for optimal asparagine (Asn) deamination by asparaginases (ASNase) in vivo (CCG-1961). Proc. Am Soc Clin Oncol. 22:p.808, Abstr. #3246, Chicago, Ill, 2003.

Grigoryan, R.S., Panosyan, E.H., Avramis, I.A., Seibel, N.L., Gaynon, P.S., Siegel, S.E., and Avramis, V.I. Correlation of 3 essential and 4 non-essential amino acid (AA) levels with asparaginase (ASNase) concentrations in serum of higher risk acute lymphoblastic leukemia (HR ALL) pediatric patients (pts) after chemotherapy (Tx) (CCG-1961). Proc. Am Soc Clin Oncol. 22:p.812, Abstr. #3265, Chicago, Ill, 2003.

Panosyan, E. H., Grigorian, R.S., Avramis, I.A., Jaques, J.D., Seibel, N.L., Ettinger, L.J., Gaynon, P.S., Siegel, S.E., Fingert, H.J., and Avramis, V.I. Asparaginase (ASNase) activity, amino acid serum concentrations, and clinical outcome in pediatric patients with higher risk acute lymphoblastic leukemia (HR ALL): A report from CCG-1961. Blood, 102(11):p378a, Abstr.#1374, 2003.

Panosyan, E.H., Seibel, N.L., Grigorian, R.S., Avramis, I.A., Jaques, J.D., Ettinger L.J., Gaynon, P.S., Sather, H.N., Franklin, J., Fu, C.H., Siegel, S.E., Fingert, H.J., and Avramis, V.I. Pharmacokinetics and pharmacodynamics of three asparaginases in pediatric patients with higher risk acute lymphoblastic leukemia: A report from CCG-1961. Blood 104 (11): p751a, Abstr.#2745, San Diego, CA, 2004.

Arce, F.J., Seibel, N., Gaynon, P. S., Tiwari, P. N., Avramis, I. A., Ettinger, L. J., Sather, H. N., Franklin, J., Fu, C., Siegel, S. E., and Avramis, V.I. Pharmacokinetics and Pharmacodynamics of Asparaginases in antibody-negative pediatric patients with higher risk acute lymphoblastic leukemia (ALL): A report from CCG-1961. Proc. Am. Assoc. Clin Oncol. 24: p508, Abstr.# 9027, 2006.

Avramis, I. A. E. H. Panosyan, F. Dorey, J. S. Holcenberg, V. I. Avramis. Vascular endothelial growth factor (VEGF-A) serum levels in standard risk ALL pediatric patients (CCG-1962 study). Proc. Am. Assoc. Clin Oncol. 24: p508, Abstr.# 9026, 2006.

Patents

Patent Inventor for Patent Application for Novartis Pharma, AG, on Anti-angiogenesis, Case # 4-32344A/CHL. All rights belong to Novartis Pharma, AG. This patent application is based on the following publications:

Avramis I. A., Christodoulopoulos G., Suzuki A., Laug W.E., Gonzalez-Gomez I., McNamara G., Sausville E.A., Avramis V.I. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother. Pharmacol., 50(6):479-489, 2002.

Avramis, I. A., Laug, W.E., Sausville, E.A., and Avramis, V. I. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (Adaphostin) and STI571 (Imatinib Mesylate, GLEEVEC) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother. Pharmacol., 52(4):307-318, 2003.